Publications

Publications acknowledging COST Action BM1204 were:

Scientific publications

2013

  • Milne R, La Vecchia C, Van Steen K, Hahn S, Buchholz M, Costello E, Esposito I, Hoheisel JD, Lange B, Lopez-Bigas N, Michalski CW, Real FX, Brand A, Malats N, on behalf of the COST Action BM1204 participants. EU Pancreas - An Integrated European Platform for Pancreas Cancer Research: from Basic Science to Clinical and Public Health Interventions for a Rare Disease. Public Health Genomics 2013;16(6):305-12.

2014

  • M Malvezzi, PQ Bertuccio, F Levi, C La Vecchia, E Negri. European cancer mortality predictions for the year 2014. Ann Oncol. 2014;25(8):1650-6.
  • Gadaleta F, Van Steen K. Discovering main genetic interactions with LABNet LAsso-based network inference. PLoS One. 2014;9(11):e110451.
  • Esposito I, Konukiewitz B, Schlitter AM, Klöppel G. Pathology of pancreatic ductal adenocarcinoma: facts, challenges and future developments. World J Gastroenterol. 2014;20(38):13833-41.

2015

  • Malvezzi M, Bertuccio P, Rosso T, Rota M, Levi F, La Vecchia C, Negri E. European cancer mortality predictions for the year 2015: does lung cancer have the highest death rate in EU women? Ann Oncol. 2015;26(4):779-86.
  • Jenkinson C, Earl J, Ghaneh P, Halloran C, Carrato A, Greenhalf W, Neoptolemos J, Costello E. Biomarkers for early diagnosis of pancreatic cancer. Expert Rev Gastroenterol Hepatol. 2015;9(3):305-15.
  • Stefek M, Soltesova Prnova M, Majekova M, Rechlin C, Heine A, Klebe G. Identification of novel aldose reductase inhibitors based on carboxymethylated mercaptotriazinoindole scaffold. J Med Chem. 2015;58:2649-57. ISSN 0022-2623.
  • Viskupicova J, Majekova M, Horakova L.. Inhibition of the sarco/endoplasmic reticulum Ca2+-ATPase (SERCA1) by rutin derivatives. J. Muscle Res Cell Motil. 2015;36:183-94. ISSN 0142-4319.
  • Mocci E, Guillen-Ponce C, Earl J, Marquez M, Solera J, Salazar-López MT, Calcedo-Arnáiz C, Vázquez-Sequeiros E, Montans J, Muñoz-Beltrán M, Vicente-Bártulos A, González-Gordaliza C, Sanjuanbenito A, Guerrero C, Mendía E, Lisa E, Lobo E, Martínez JC, Real FX, Malats N, Carrato A. PanGen-Fam: Spanish registry of hereditary pancreatic cancer. Eur J Cancer. 2015;51(14):1911-7.
  • Earl J, Garcia-Nieto S, Martinez-Avila JC, Montans J, Sanjuanbenito A, Rodríguez-Garrote M, Lisa E, Mendía E, Lobo E, Malats N, Carrato A, Guillen-Ponce C. Circulating tumor cells (Ctc) and kras mutant circulating free Dna (cfdna) detection in peripheral blood as biomarkers in patients diagnosed with exocrine pancreatic cancer. BMC Cancer. 2015;15:797.
  • Esposito I, Segler A, Steiger K, Klöppel G. Pathology, genetics and precursors of human and experimental pancreatic neoplasms: An update. Pancreatology. 2015;pii: S1424-3903(15)00632-8.
  • Pineda S, Real FX, Kogevinas M, Carrato A, Chanock SJ, Malats N, Van Steen K. Integration Analysis of Three Omics Data Using Penalized Regression Methods: An Application to Bladder Cancer. PLoS Genet. 2015 Dec 8;11(12):e1005689.
  • Gomez-Rubio P, Zock JP, Rava M, Marquez M, Sharp L, Hidalgo M, Carrato A, Ilzarbe L, Michalski C, Molero X, Farré A, Perea J, Greenhalf W, O'Rorke M, Tardón A, Gress T, Barberà V, Crnogorac-Jurcevic T, Domínguez-Muñoz E, Muñoz-Bellvís L, Alvarez-Urturi C, Balcells J, Barneo L, Costello E, Guillén-Ponce C, Kleeff J, Kong B, Lawlor R, Löhr M, Mora J, Murray L, O'Driscoll D, Peláez P, Poves I, Scarpa A, Real FX, Malats N; PanGenEU Study Investigators. Reduced risk of pancreatic cancer associated with asthma and nasal allergies. Gut. 2015 Dec 1. pii: gutjnl-2015-310442. doi: 10.1136/gutjnl-2015-310442. [Epub ahead of print]
  • Ligat L, Saint-Laurent N, El-Mrani A, Gigoux V, Al Saati T, Tomasini R4, Nigri J, Dejean S, Pont F, Baer R, Guillermet-Guibert J, Cordelier P, Lopez F, Dufresne M. Pancreatic preneoplastic lesions plasma signatures and biomarkers based on proteome profiling of mouse models. Br J Cancer. 2015;113(11):1590-8.
  • Prnova MS, Ballekova J, Majekova M, Stefek M. Antioxidant action of 3-mercapto-5H-1,2,4-triazino[5,6-b]indole-5-acetic acid, an efficient aldose reductase inhibitor, in a 1,1'-diphenyl-2-picrylhydrazyl assay and in the cellular system of isolated erythrocytes exposed to tert-butyl hydroperoxide. Redox Rep. 2015;20(6):282-8.

2016

2017

  • Malvezzi M, Carioli G, Bertuccio P, Boffetta P, Levi F, La Vecchia C, Negri E. European cancer mortality predictions for the year 2017, with focus on lung cancer. Ann Oncol. 2017 Feb 21. doi: 10.1093/annonc/mdx033. [Epub ahead of print]
  • Villanueva, Eneko; Navarro, Pilar; Rovira-Rigau, Maria; et ál..Translational reprogramming in tumour cells can generate oncoselectivity in viral therapies Nat Commun. 2017 Mar 16;8:14833. doi: 10.1038/ncomms14833.
  • Gomez-Rubio P, Rosato V, Marquez M, Bosetti C, Molina-Montes E, Rava M, Piñero J, Michalski CW, Farré A, Molero X, Löhr M, Ilzarbe L, Perea J, Greenhalf W, O'Rorke M, Tardón A, Gress T, Barberà VM, Crnogorac-Jurcevic T, Muñoz-Bellvís L, Domínguez-Muñoz E, Gutiérrez-Sacristán A, Balsells J, Costello E, Guillén-Ponce C, Huang J, Iglesias M, Kleeff J, Kong B, Mora J, Murray L, O'Driscoll D, Peláez P, Poves I, Lawlor RT, Carrato A, Hidalgo M, Scarpa A, Sharp L, Furlong LI, Real FX, La Vecchia C, Malats N; PanGenEU Study Investigators. A systems approach identifies time-dependent associations of multimorbidities with pancreatic cancer risk. Ann Oncol. 2017 Apr 5. doi: 10.1093/annonc/mdx167. [Epub ahead of print].
  • Malats N, Molina-Montes E, La Vecchia C. Genomics in primary and secondary prevention of pancreatic cancer. Public Health Genomics J 2017 (in press). PMID: 477234.
  • Martin MA, Alonso MD, Madrid M, López de Maturana E, Malats N. DoriTool: A bioinformatics integrative tool for post-association functional annotation. Public Health Genomics 2017 (in press).

Book Chapters

Two book chapters on the Action scientific-related interests have been published in 2014:

  • (1) Kristel Van Steenand Núria Malats, on behalf of the COST Action BM1204 participants. Perspectives on Data Integration in Human Complex Disease Analysi. In: Big data analytics in Bioinformatics and Healthcare. Pages: 284-322. Available at Irma International.
  • (2) Enrique Carrillo-de Santa Pau, Francisco X. Real, Alfonso Valencia. Bioinformatics analysis of pancreas cancer genome in high-throughput genomic Technologies. In Molecular Diagnostics and Treatment of pancreatic cancer. Pages: 93-131.
  • (3) Kristel Van Steen and Núria Malats, on behalf of the COST Action BM1204 participants. Neostrategies in integrating omics data in pancreatic cancer. (Under revision)

Reports

Two reports based on the European Alliance for Personalised Medicine (EAPM) survey "Barriers in access to Personalised Medicine" on pancreas cancer have been prepared by WG4:

"The Pancreatic Cancer White Paper"

The pancreatic cancer white paper

The Pancreatic Cancer While Paper was launched by the EAMP in collaboration with EUPancreas (WG4). It is a direct appeal to policymakers, legislators, and regulators to encourage innovation, to enhance prevention, and to broaden access to treatment. It also calls on all stakeholders to work more closely together to reduce the burden of pancreatic cancer on patients and on society.

+ press release and white paper

Oral/Poster presentations of the COST Action BM1204 were presented at:

  • PanC4 meeting (Baltimore, March 2013) by N Malats.
  • Club Français du Pancreas XXVIII meeting (Amiens, September 2013) by M Dufresne.
  • ICGC-pancreas meeting 2013 (Toronto, October 2013) by N Malats.
  • FP7/H2020 Meeting (Dublin, November 2013) by N Malats.
  • Pancreas Society of Great Britain 39th meeting (Liverpool, November 2013) by E Costello-Goldring.
  • Annual meeting of the Spanish Society of Epidemiology (Alicante, September 2014) by N Malats.
  • 3rd European Alliance for Personalised Medicine (EAPM) Annual Conference (Brussel, June 2015) by N Malats and A Brand.
  • Taking Stock: Where we are now and the necessary next steps to take to realize an environment for personalized medicine. 6th April 2016 Brussel, Belgium.
  • "Polish Pancreatic Cancer Club Meeting" (Ossa, 23-26 June 2016) by Ewa Małecka-Panas

Scientific Workshops/Conferences organized or supported by the COST Action BM1204:

  • "First Annual Conference" jointly organized with the "Pancreatic Cancer Forum - 2013". 5-7th November 2013. Madrid, Spain.
  • "Integromics" workshop. February 2014. Heidelberg, Germany.
  • "The London Pancreatic Workshop 2014. A forum for state of the art clinical and basic research in pancreatic cancer″. 2nd May 2014. Bart's Cancer Inst. London, Uk.
  • "The first pancreatic cystic tumour patient forum". 3rd October 2014. Royal Free Hospital, London.
  • "Capita Selecta in Complex Disease Analysis". 24-26th November 2014. Liège, Belgium.
  • The 47th Annual Meeting of the European Pancreatic Club. 23–27th June 2015. Toledo, Spain.
  • "Cancer genomics and personalised medicine workshop: focus on pancreas cancer". 1st July 2015. Barcelona, Spain.
  • WG4 TRAINING SCHOOL on "Genomics and Genthics". 10-15th September 2015. Aegina, Greece.
  • Workshop on Pancreatic Cancer. Towards a Clinical Registry of Pancreatic Cancer: PancreOS. 5th October 2015. Madrid, Spain.
  • PancreOS kick-off meeting. 17th March 2016. Madrid, Spain.
  • WG2 TRAINING SCHOOL on "Interactions in Complex Disease Analysis. The world of interactions around us" 27-29 April 2015. Antwerp, Belgium.
  • WG3 TRAINING SCHOOL on "GENOMIC MEDICINE - Bridging research and the clinic" 3-6 May 2006. Portoroz, Slovenia.

Press releases referring to the COST Action BM1204: